多西他赛联合表柔比星、环磷酰胺治疗转移性乳腺癌的临床观察

目的：观察多西他赛联合表柔比星、环磷酰胺治疗转移性乳腺癌的临床疗效及不良反应。方法：回顾性分析40例转移性乳腺癌患者的化疗资料,采用国产多西他赛75mg/m2,表柔比星70-90mg/m2静脉滴注,环磷酰胺500mg/m2每3周1次。观察每次化疗后的不良反应,完成4个疗程后观察疗效。结果：全部病例均按计划完成4个周期的化疗。完全缓解（CR）3例,部分缓解（PR）20例,稳定（SD）12例,进展（PD）5例。总有效率（CR＋PR）为57.5%,控制率（CR＋PR＋SD）87.5%。主要不良反应为中性粒细胞减少、恶心、呕吐、腹泻等。结论：多西他赛联合表柔比星、环磷酰胺治疗转移性乳腺癌临床疗效较好,不良反应患者可以耐受。

Clinical study of docetaxel,epirubicin and cyclophosphamide combination in the treatment of patients with metastatic breast cancer

Objective：To evaluate the efficacy and toxicity of docetaxel,epirubicin and cyclophosphamide combination in the treatment of patients with metastatic breast cancer.Methods： Data of forty patients with metastatic breast cancer treated with docetaxel 75mg/m2,epirubicin 50mg/m2 and cyclophosphamide 500mg/m2 for 4 cycles were analysed.Results： The overall response rate was 57.5% with 3 CR and 20 PR.SD was 12,PD was 5.The tumor control rate（CR＋PR＋SD）was 87.5%.The main toxic reactions were leucopenia,nausea,vomiting and diarrhea,and were tolerable.Conclusion： Good clinical efficacy was achieved in the therapy of metastalic breast cancer with docelaxel,epirubicin and cyclophosphamide combination regimen and toxic reactions are tolerable.